Portola Pharmaceuticals Net Income

The latest net income for PTLA is $-280M as of March 2020. That compares with $-340M in the prior-year period — up 18.3% year over year. That is below the Healthcare sector average of $16B. Investors often review this figure alongside Portola Pharmaceuticals's historical trend and sector peers before judging valuation or financial health.

Over the past year, PTLA's net income moved from $-340M to $-280M — a 18.3% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Portola Pharmaceuticals's operating scale or balance-sheet position.

Against Healthcare companies, PTLA currently prints $-280M for net income, while the sector average sits near $16B. That is roughly 101.8% below the sector mean. Large gaps often invite a closer look at Portola Pharmaceuticals's growth, margins, and balance sheet.

A net income figure of $-280M for PTLA is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $16B. Explore the charts below for those layers of context.

After noting PTLA's net income ($-280M), review year-over-year change from $-340M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.